NCT00797472 - Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Hodgkin's Disease

Interventions

DRUG

R-mabHD

An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.

DRUG

ABVD

A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.

Trial Locations (1)

07726

Raritan Bay Medical Center, Englishtown